Go Deep
MaxCyte, Inc.
MaxCyte, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,937 | -3.8 | 0.84 | 0.11 | 123.13 |
| Oct 2026 | 19,937 | -3.8 | 0.84 | 0.11 | 123.13 |
| Oct 2026 | 18,137 | -3.8 | 0.84 | 0.11 | 123.26 |
| Oct 2026 | 17,734 | -4.2 | 0.93 | 0.11 | 135.59 |
| Oct 2026 | 17,611 | -4.3 | 0.96 | 0.11 | 139.04 |
| Oct 2026 | 17,734 | -4.2 | 0.93 | 0.11 | 134.98 |
MaxCyte, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 7,271,000.0 | 9,651,000.0 | 7,300,000.0 | 6,829,000.0 |
| Net Profit | -8,874,000.0 | -4,750,000.0 | -9,596,000.0 | -12,416,000.0 |
| EPS | -0.1 | -0.0 | -0.1 | -0.1 |
MaxCyte, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 33,026,000.0 | 38,627,000.0 | 41,288,000.0 | 44,261,000.0 | — |
| Net Profit | -44,630,000.0 | -41,055,000.0 | -37,923,000.0 | -23,571,000.0 | — |
| EPS | -0.4 | -0.4 | -0.4 | -0.2 | — |
MaxCyte, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 202,507,000.0 | 239,470,000.0 | 268,274,000.0 | 286,653,000.0 | — |
| Total Liabilities | 31,017,000.0 | 33,219,000.0 | 36,107,000.0 | 32,685,000.0 | — |
| Total Equity | 171,490,000.0 | 206,251,000.0 | 232,167,000.0 | 253,968,000.0 | — |
Owes vs Owns
MaxCyte, Inc. owed $0.14 for every $1 it owned in Jun 2026, up from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.15× | 0.14× | 0.13× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
MaxCyte, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 50.9%Receivables 1.7%Inventory 3.7%Fixed assets (tangible) 14.0%Long-term investments 26.0%Other assets 3.3%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 8.1%Payables 0.7%Other liabilities 5.8%Shareholders' equity 84.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 103.0 | 154.5 | 168.3 | 227.3 |
| Receivables | 3.5 | 4.7 | 5.8 | 13.1 |
| Inventory | 7.5 | 8.9 | 12.2 | 8.6 |
| Fixed assets (tangible) | 28.5 | 30.5 | 34.8 | 33.6 |
| Intangible assets | 0.7 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 52.6 | 35.8 | 42.9 | 0.0 |
| Other assets | 6.7 | 5.1 | 4.3 | 4.1 |
| Liabilities & equity | ||||
| Short-term debt | 1.5 | 0.9 | 0.8 | 0.2 |
| Long-term debt | 16.5 | 17.2 | 18.0 | 15.9 |
| Payables | 1.4 | 1.4 | 0.7 | 0.3 |
| Other liabilities | 11.7 | 13.8 | 16.6 | 16.3 |
| Shareholders' equity | 171.5 | 206.3 | 232.2 | 254.0 |
| Net tangible assets | 170.8 | 206.3 | 232.2 | 254.0 |
MaxCyte, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -34,410,000.0 | -27,610,000.0 | -21,686,000.0 | -14,783,000.0 | — |
| Investing Activities | 25,935,000.0 | 6,932,000.0 | 54,984,000.0 | -24,823,000.0 | — |
| Financing Activities | 656,000.0 | 2,056,000.0 | 2,143,000.0 | 2,888,000.0 | — |